The PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor is a PI (phosphoinositide) 3-phosphatase that may inhibit mobile proliferation, survival and progress by inactivating PI 3-kinase-dependent signalling. It additionally suppresses mobile motility via mechanisms which may be partially unbiased of phosphatase exercise.
PTEN is among the mostly misplaced tumour suppressors in human most cancers, and its deregulation can also be implicated in a number of different ailments. Right here we talk about current developments in our understanding of how the mobile exercise of PTEN is regulated, and the carefully associated query of how this exercise is misplaced in tumours.
Mobile PTEN perform seems to be regulated by controlling each the expression of the enzyme and likewise its exercise via mechanisms together with oxidation and phosphorylation-based management of non-substrate membrane binding. Subsequently mutation of PTEN in tumours disrupts not solely the catalytic perform of PTEN, but in addition its regulatory features.
Nonetheless, though mutation of PTEN is unusual in lots of human tumour sorts, lack of PTEN expression appears to be extra frequent. It’s presently unclear how these tumours lose PTEN expression within the absence of mutation, and whereas some information implicate different potential tumour suppressors and oncogenes on this course of, this space appears prone to be a key focus of future analysis.
The mitochondrial permeability transition pore and its involvement in cell dying and in illness pathogenesis.
Present analysis on the mitochondrial permeability transition pore (PTP) and its function in cell dying faces a paradox. Initially thought of as an in vitro artifact of little pathophysiological relevance, in recent times the PTP has obtained appreciable consideration as a possible mechanism for the execution of cell dying.
The current profitable use of PTP desensitizers in a number of illness paradigms leaves little doubt about its relevance in pathophysiology; and rising findings that hyperlink the PTP to key mobile signalling pathways are growing the curiosity on the pore as a pharmacological goal.
But, current genetic information have challenged in style views on the molecular nature of the PTP, and known as into query many early conclusions about its construction. Right here we evaluate fundamental ideas about PTP construction, perform and regulation inside the framework of intramobile dying signalling, and its function in illness pathogenesis.
Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase.
The interferon (IFN)-induced mobile antiviral response is the primary line of protection towards viral an infection inside an animal host. As a way to set up a productive an infection, eukaryotic viruses should first overcome the IFN-induced blocks imposed on viral replication.
The double-stranded RNA-activated protein kinase (PKR) is a key element mediating the antiviral actions of IFN. This IFN-induced protein kinase can limit viral replication via its capability to phosphorylate the protein synthesis initiation issue eukaryotic initiation factor-2 alpha-subunit and scale back ranges of viral protein synthesis. Viruses, subsequently, should block the perform of PKR to be able to keep away from these deleterious antiviral results related to PKR exercise.
Certainly, many viruses have developed efficient measures to repress PKR exercise throughout an infection. This evaluate will focus totally on an summary of the completely different molecular mechanisms employed by these viruses to fulfill a typical objective: the inhibition of PKR perform, uncompromised viral protein synthesis, and unrestricted virus replication.
The previous few years have seen thrilling new advances on this space. Reasonably unexpectedly, this space of analysis has benefited from the usage of the yeast system to review PKR. Different current advances embody research on PKR regulation by the herpes simplex viruses and information from our laboratory on the medically vital hepatitis C viruses.
We speculate that IFN is ineffective as a therapeutic agent towards hepatitis C virus as a result of the virus can successfully repress PKR perform. Lastly, we are going to talk about briefly the longer term instructions of this PKR discipline.
Adrenomedullin, a multifunctional regulatory peptide.
Because the discovery of adrenomedullin in 1993 a number of hundred papers have been printed relating to the regulation of its secretion and the multiplicity of its actions. It has been proven to be an nearly ubiquitous peptide, with the variety of tissues and cell sorts synthesizing adrenomedullin far exceeding these that don’t.
In Part II of this paper we give a complete evaluate each of tissues and cell traces secreting adrenomedullin and of the mechanisms regulating gene expression. The information on circulating adrenomedullin, obtained with the assorted assays accessible, are additionally reviewed, and the illness states wherein plasma adrenomedullin is elevated are listed.
In Part III the pharmacology and biochemistry of adrenomedullin binding websites, each particular websites and calcitonin gene-related peptide (CGRP) receptors, are mentioned. Particularly, the putative adrenomedullin receptor clones and sign transduction pathways are described.
In Part IV the assorted actions of adrenomedullin are mentioned: its actions on mobile progress, the cardiovascular system, the central nervous system, and the endocrine system are all thought of. Lastly, in Part V, we take into account some unresolved points and suggest future areas for analysis.
International phenotypic characterization of micro organism.
The measure of the standard of a programs biology mannequin is how properly it could possibly reproduce and predict the behaviors of a organic system reminiscent of a microbial cell.
Lately, these fashions have been constructed up in layers, and every layer has been rising in sophistication and accuracy in parallel with a worldwide information set to problem and validate the fashions in predicting the content material or actions of genes (genomics), proteins (proteomics), metabolites (metabolomics), and in the end cell phenotypes (phenomics).
This evaluate focuses on the latter, the phenotypes of microbial cells. The event of Phenotype MicroArrays, which try to offer a worldwide view of mobile phenotypes, is described.
 CD45RA |
|||
| 45RAF1-100T | ImmunoStep | 100 test | EUR 387.6 |
CD45RA |
|||
| 45RAF2-100T | ImmunoStep | 100 test | EUR 356.4 |
CD45RA |
|||
| 45RAPE1-100T | ImmunoStep | 100 test | EUR 621.6 |
CD45RA |
|||
| 45RAPE2-100T | ImmunoStep | 100 test | EUR 418.8 |
CD45RA |
|||
| 45RAPP2-100T | ImmunoStep | 100 test | EUR 418.8 |
CD45RA |
|||
| 45RAPU1-01MG | ImmunoStep | 0,1 mg | EUR 262.8 |
CD45RA |
|||
| 45RAPU2-01MG | ImmunoStep | 0,1 mg | EUR 262.8 |
 Antibody) CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx413329-01mg | Abbexa | 0.1 mg | EUR 543.6 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx413626-2ml | Abbexa | 2 ml | EUR 727.2 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx415596-02mg | Abbexa | 0.2 mg | EUR 678 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx415611-20ug | Abbexa | 20 ug | EUR 326.4 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx414688-1mg | Abbexa | 1 mg | EUR 994.8 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx414689-01mg | Abbexa | 0.1 mg | EUR 526.8 |
CD45RA Antigen (CD45RA/PTPRC) Antibody |
|||
| abx414691-025mg | Abbexa | 0.25 mg | EUR 678 |
 Antibody (RPE)) CD45RA Antigen (CD45RA/PTPRC) Antibody (RPE) |
|||
| abx413330-100tests | Abbexa | 100 tests | EUR 861.6 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (RPE) |
|||
| abx415610-100tests | Abbexa | 100 tests | EUR 710.4 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (RPE) |
|||
| abx414690-100tests | Abbexa | 100 tests | EUR 710.4 |
 Antibody (FITC)) CD45RA Antigen (CD45RA/PTPRC) Antibody (FITC) |
|||
| abx413328-01mg | Abbexa | 0.1 mg | EUR 777.6 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (FITC) |
|||
| abx415608-01mg | Abbexa | 0.1 mg | EUR 610.8 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (FITC) |
|||
| abx415609-25ug | Abbexa | 25 ug | EUR 326.4 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (FITC) |
|||
| abx414287-01mg | Abbexa | 0.1 mg | EUR 610.8 |
CD45RA Antigen (CD45RA/PTPRC) Antibody (FITC) |
|||
| abx414687-01mg | Abbexa | 0.1 mg | EUR 610.8 |
 CD4/CD45RA |
|||
| 4F45RAPE2-50T | ImmunoStep | 50 test | EUR 626.28 |
 CD45RA/CD4 |
|||
| 45RAF24PE1-50T | ImmunoStep | 50 test | EUR 437.52 |
 CD45RA Antibody |
|||
| abx200318-100ug | Abbexa | 100 ug | EUR 393.6 |
CD45RA Antibody |
|||
| abx200322-100ug | Abbexa | 100 ug | EUR 393.6 |
CD45RA Antibody |
|||
| abx139821-01mg | Abbexa | 0.1 mg | EUR 427.2 |
CD45RA Antibody |
|||
| 20-abx134010 | Abbexa |
|
|
 CD45RA antibody |
|||
| 10-Z45R | Fitzgerald | 800 ug | EUR 296.4 |
|
Description: Mouse monoclonal CD45RA antibody |
|||
CD45RA antibody |
|||
| 10R-6408 | Fitzgerald | 100 ug | EUR 249.6 |
|
Description: Mouse monoclonal CD45RA antibody |
|||
 Antibody) CD45RA(111-1C5) Antibody |
|||
| BNC941038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC941038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF594 conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) CD45RA(158-4D3) Antibody |
|||
| BNCA0028-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(158-4D3), APC conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC801038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC801038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC810028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC810028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC800028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC800028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC811038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC811038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC940028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC940028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC701038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC701038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC881038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC881038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC880028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC880028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC051038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC051038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC041038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC041038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC430028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC430028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC400028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC400028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC401038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC401038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF640R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC050028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC050028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF405M conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCB0028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCB1038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCB1038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCAP1038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCAP1038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCA1038-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(111-1C5), APC conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCAP0028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCAP0028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCB0028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Biotin conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCR0028-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(158-4D3), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCR1038-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(111-1C5), RPE conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNUB0028-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Concentration: 0.2mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNUB0028-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against CD45RA(158-4D3), Concentration: 0.2mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCP0028-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(158-4D3), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCP1038-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against CD45RA(111-1C5), PerCP conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCH0028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNCH0028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNUM0028-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD45RA(158-4D3), 1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNUM1038-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against CD45RA(111-1C5), 1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCH1038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNCH1038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNUB1038-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against CD45RA(111-1C5), Concentration: 0.2mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNUB1038-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against CD45RA(111-1C5), Concentration: 0.2mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC040028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC040028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF405S conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC550028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC550028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC610028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC610028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC611038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC611038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF660R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC680028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC680028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC470028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC470028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC551038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC551038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF555 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC431038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC431038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF543 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC700028-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(158-4D3) Antibody |
|||
| BNC700028-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(158-4D3), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC681038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC681038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF568 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC471038-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF647 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(111-1C5) Antibody |
|||
| BNC471038-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(111-1C5), CF647 conjugate, Concentration: 0.1mg/mL |
|||
) CD45RA Antibody (PE) |
|||
| abx200320-100tests | Abbexa | 100 tests | EUR 727.2 |
CD45RA Antibody (PE) |
|||
| abx200324-100tests | Abbexa | 100 tests | EUR 543.6 |
CD45RA Antibody (PE) |
|||
| abx139831-100tests | Abbexa | 100 tests | EUR 577.2 |
CD45RA Antibody (PE) |
|||
| abx134004-100Assays | Abbexa | 100 Assays | EUR 526.8 |
CD45RA Antibody (PE) |
|||
| abx134004-50Assays | Abbexa | 50 Assays | EUR 410.4 |
) CD45RA Antibody (APC) |
|||
| abx200325-100tests | Abbexa | 100 tests | EUR 543.6 |
CD45RA Antibody (APC) |
|||
| abx139832-100tests | Abbexa | 100 tests | EUR 577.2 |
) CD45RA Antibody (FITC) |
|||
| abx200319-100tests | Abbexa | 100 tests | EUR 510 |
CD45RA Antibody (FITC) |
|||
| abx200323-100tests | Abbexa | 100 tests | EUR 477.6 |
CD45RA Antibody (FITC) |
|||
| abx139834-100tests | Abbexa | 100 tests | EUR 510 |
CD45RA Antibody (FITC) |
|||
| abx134000-100Assays | Abbexa | 100 Assays | EUR 526.8 |
CD45RA Antibody (FITC) |
|||
| abx134000-50Assays | Abbexa | 50 Assays | EUR 410.4 |
) CD45RA Antibody (PerCP) |
|||
| abx200326-100tests | Abbexa | 100 tests | EUR 543.6 |
CD45RA Antibody (PerCP) |
|||
| abx139830-100tests | Abbexa | 100 tests | EUR 577.2 |
 CD45RA/CD45RO/CD3/CD4 |
|||
| 45RAF245ROPE3PP14A1-50T | ImmunoStep | 50 test | EUR 730.8 |
 CD45RA/CD45RO/CD3/CD8 |
|||
| 45RAF245ROPE3PP18A3-50T | ImmunoStep | 50 test | EUR 730.8 |
) CD45RA Antibody (Biotin) |
|||
| abx200327-100ug | Abbexa | 100 ug | EUR 460.8 |
CD45RA Antibody (Biotin) |
|||
| abx139833-01mg | Abbexa | 0.1 mg | EUR 510 |
CD45RA Antibody (Biotin) |
|||
| abx133997-100Assays | Abbexa | 100 Assays | EUR 526.8 |
CD45RA Antibody (Biotin) |
|||
| abx133997-50Assays | Abbexa | 50 Assays | EUR 410.4 |
) CD45RA antibody (biotin) |
|||
| 61R-1507 | Fitzgerald | 100 ug | EUR 360 |
|
Description: Mouse monoclonal CD45RA antibody (biotin) |
|||
 CD45RA/CD62L/CD3/CD4 |
|||
| 45RAF262LPE3PP14A1-50T | ImmunoStep | 50 test | EUR 730.8 |
 CD45RA/CD62L/CD3/CD8 |
|||
| 45RAF262LPE3PP18A3-50T | ImmunoStep | 50 test | EUR 730.8 |
 Anti-Hu CD45RA PE |
|||
| 1P-223-T025 | ExBio | 25 tests | EUR 168 |
Anti-Hu CD45RA PE |
|||
| 1P-223-T100 | ExBio | 100 tests | EUR 288 |
 Anti-Hu CD45RA APC |
|||
| 1A-223-T025 | ExBio | 25 tests | EUR 168 |
Anti-Hu CD45RA APC |
|||
| 1A-223-T100 | ExBio | 100 tests | EUR 288 |
 Anti-Hu CD45RA FITC |
|||
| 1F-223-T025 | ExBio | 25 tests | EUR 146.4 |
Anti-Hu CD45RA FITC |
|||
| 1F-223-T100 | ExBio | 100 tests | EUR 244.8 |
 Anti-Hu CD45RA PerCP |
|||
| PC-223-T025 | ExBio | 25 tests | EUR 168 |
Anti-Hu CD45RA PerCP |
|||
| PC-223-T100 | ExBio | 100 tests | EUR 288 |
) CD45RA antibody (allophycocyanin) |
|||
| 61R-1736 | Fitzgerald | 100 tests | EUR 548.4 |
|
Description: Mouse monoclonal CD45RA antibody (allophycocyanin) |
|||
 Anti-Hu CD45RA Biotin |
|||
| 1B-223-C025 | ExBio | 0.025 mg | EUR 146.4 |
Anti-Hu CD45RA Biotin |
|||
| 1B-223-C100 | ExBio | 0.1 mg | EUR 244.8 |
 Antibody) CD45RA(PTPRC/1131) Antibody |
|||
| BNC941131-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC941131-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF594 conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) CD45RA(PTPRC/1148) Antibody |
|||
| BNC941148-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC941148-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC801131-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC801131-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC801148-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC801148-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF680 conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) CD45RA(PTPRC/818) Antibody |
|||
| BNC800818-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC800818-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF680 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC810818-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC810818-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC811131-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC811131-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC811148-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC811148-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF680R conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC940818-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC940818-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF594 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC700818-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC700818-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC701131-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC701131-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC701148-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC701148-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC880818-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/818) Antibody |
|||
| BNC880818-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/818), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC881131-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1131) Antibody |
|||
| BNC881131-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1131), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC881148-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF488A conjugate, Concentration: 0.1mg/mL |
|||
CD45RA(PTPRC/1148) Antibody |
|||
| BNC881148-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against CD45RA(PTPRC/1148), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Along with their use in fleshing out and validating programs biology fashions, there are lots of different makes use of of this international phenotyping know-how in fundamental and utilized microbiology analysis, that are additionally described.